In this paper, we focused on the next generation sequencing gene panels and did not consider routine tumor molecular profiling that may involve multiple assessments, each of which targets a single gene or type of mutation (e.g. HER2, BRCA1, BRCA2 in breast cancer, and EGFR, HER2, KRAS, and ALK in lung cancer). Here, ALK is linked to neoplasm.